Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics

Mallinckrodt plc Ordinary Shares (MNK)

Today's Latest Price: $2.50 USD

0.18 (-6.72%)

Updated Jul 1 4:10pm

Add MNK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MNK Stock Summary

  • MNK's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.29 -- higher than just 5.39% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Mallinckrodt plc is higher than merely 3.51% of stocks in our set with a positive cash flow.
  • MNK's price/sales ratio is 0.07; that's higher than the P/S ratio of just 3.3% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Mallinckrodt plc, a group of peers worth examining would be OSMT, SCOR, ROSE, CPLG, and AR.
  • Visit MNK's SEC page to see the company's official filings. To visit the company's web site, go to
MNK Daily Price Range
MNK 52-Week Price Range

MNK Stock Price Chart Technical Analysis Charts

MNK Price/Volume Stats

Current price $2.50 52-week high $9.20
Prev. close $2.68 52-week low $1.00
Day low $2.48 Volume 3,411,699
Day high $2.77 Avg. volume 6,997,710
50-day MA $3.02 Dividend yield N/A
200-day MA $3.25 Market Cap 211.14M

Mallinckrodt plc Ordinary Shares (MNK) Company Bio

Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.

MNK Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Mallinckrodt plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mallinckrodt plc ranked in the 87th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for MNK, they are:

  • 4% of the company's capital comes from equity, which is greater than only 1.42% of stocks in our cash flow based forecasting set.
  • Mallinckrodt plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -4.32. This coverage rate is greater than that of only 12.33% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 18. This value is greater than 99.57% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MNK, try ARGX, SUPN, ASRT, ASNB, and BEAT.

MNK Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MNK Latest Social Stream

Loading social stream, please wait...

View Full MNK Social Stream

Latest MNK News From Around the Web

Below are the latest news stories about Mallinckrodt plc that investors may wish to consider to help them evaluate MNK as an investment opportunity.

Global Radiopharmaceutical Market Outlook (2019 to 2027) - Featuring Mallinckrodt, Bayer & Siemens Healthineers Among Others -

DUBLIN--(BUSINESS WIRE)--The "Radiopharmaceutical - Global Market Outlook (2019-2027)" report has been added to's offering. The Global Radiopharmaceutical market accounted for $3.76 billion in 2019 and is expected to reach $5.99 billion by 2027 growing at a CAGR of 6.0% during the forecast period. Some of the key factors propelling market growth are technological advancements in the diagnostics sector, increasing prevalence of cancer, and increasing applications of molecu

Business Wire | June 24, 2020

Beyond Air: COVID-19 And More

Beyond Air, Inc. (XAIR) is a biopharmaceutical company developing medical devices that deliver nitric oxide ((NO)) to treat respiratory conditions and tumors. XAIR hasn't flown below the radar of the coronavirus hype, the name was up over 100 percent year-to-date in early March. Based on comments at a March investor...

Biotech Beast on Seeking Alpha | June 23, 2020

Hedge Funds Never Been Less Bullish On Mallinckrodt Public Limited Company (MNK)

In this article you are going to find out whether hedge funds think Mallinckrodt Public Limited Company (NYSE:MNK) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus […]

Yahoo | June 23, 2020

Opioid Actions in New York State Bode Ill for Mallinckrodt, Says Citi

“Opioid risk is coming back,” says analyst Navann Ty, who lowered her rating on the drugmaker to Sell in the face of a lawsuit and a separate investigation by the state.

Yahoo | June 17, 2020

Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference. Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: A replay of the fireside chat will also be available following the meeting.

Yahoo | June 17, 2020

Read More 'MNK' Stories Here

MNK Price Returns

1-mo -10.39%
3-mo 47.06%
6-mo -25.60%
1-year -72.19%
3-year -94.48%
5-year -97.91%
YTD -28.37%
2019 -77.91%
2018 -29.96%
2017 -54.72%
2016 -33.24%
2015 -24.64%

Continue Researching MNK

Want to see what other sources are saying about Mallinckrodt plc's financials and stock price? Try the links below:

Mallinckrodt plc (MNK) Stock Price | Nasdaq
Mallinckrodt plc (MNK) Stock Quote, History and News - Yahoo Finance
Mallinckrodt plc (MNK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9011 seconds.